inclusion criteria: * aged ≥18 years old when signing icf; * no other anti-sars-cov-2 vaccines (approved for marketing or registered study) have been previously administered; * participants can sign written icf and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study, * participants should have the ability to read, understand and fill the vaccination record card (vrc); * only for participants in phase i : those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal; * only for participants in phase ii: healthy participants or participants with stable underlying diseases; * fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing icf to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.

inclusion criteria: * aged ≥18 years old when signing icf; * no other anti-sars-cov-2 vaccines (approved for marketing or registered study) have been previously administered; * participants can sign written icf and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study, * participants should have the ability to read, understand and fill the vaccination record card (vrc); * only for participants in phase i : those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal; * only for participants in phase ii: healthy participants or participants with stable underlying diseases; * fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing icf to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.

inclusion criteria: aged ≥18 years old when signing icf; no other anti-sars-cov-2 vaccines (approved for marketing or registered study) have been previously administered; participants can sign written icf and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study, participants should have the ability to read, understand and fill the vaccination record card (vrc); only for participants in phase i : those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal; only for participants in phase ii: healthy participants or participants with stable underlying diseases; fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing icf to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.

inclusion criteria: aged ≥18 years old when signing icf; no other anti-sars-cov-2 vaccines (approved for marketing or registered study) have been previously administered; participants can sign written icf and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study, participants should have the ability to read, understand and fill the vaccination record card (vrc); only for participants in phase i : those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal; only for participants in phase ii: healthy participants or participants with stable underlying diseases; fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing icf to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.